NVO

Novo Nordisk

$50.35
+3.24% today · $228.67B mkt cap
Forensic verdict

Structurally Supported

Low risk. Claims align with the filings and valuation divergence is contained.

74%
Signal conviction
Hit rate: 48% · 27 trades
Fair-value divergence
-28.3%
Trading at a discount · fair value $69.76
Verification match
100/100
Claims vs. SEC filings
Epistemic drift
0/100
Story vs. disclosures
Source authority
77/100
Outlet credibility
Coordination
Organic spread
Cross-source timing & phrasing — score 0.
Price-impact probability
WKS +9
Neutral directional energy · ACS 84
Trading footprint
Normal activity
Tape anomaly read — distinct from the narrative signal.
Narrative decay
2d half-life
Persistent regime
Today’s strategy signals
All strategies →
No named-playbook signal fired for NVO today. These are short-term technical screens — most names don’t trigger on a given day.
Tracked price · last 90 sessions
Interactive Signal Lab →
Narrative under audit
“NVO narrative: company summary NOVO B:CPH summary (unspecified)”
Recent narratives tracked
01

NVO narrative: company summary NOVO B:CPH summary (unspecified)

02

Eli Lilly is perceived by Wall Street as the 'clear winner' in the weight-loss and diabetes drug market following new clinical trial data, though Novo Nordisk's chief scientist maintains the competition is ongoing.

03

NVO narrative: financial summary summary of company information (unspecified)

04

Novo Nordisk's Chief Science Officer believes the competition in the GLP-1 drug market is far from over, despite an analyst declaring Eli Lilly the winner of a recent American Diabetes Association conference due to positive developments in its weight-loss and diabetes drugs.

05

Eli Lilly's new weight-loss and diabetes drugs are cementing its lead over Novo Nordisk, although Novo Nordisk's chief scientist believes the GLP-1 competition is far from over.

06

Novo Nordisk (NVO) stock is experiencing opinions on an analyst upgrade and a valuation reset, influencing its market perception.

07

Pfizer's new weight-loss data introduces competitive concerns for investors in Eli Lilly and Novo Nordisk.

08

Investors are weighing whether Eli Lilly or Novo Nordisk (NVO) is the better obesity drug stock.

Go deeper on Novo Nordisk
Open the full interactive dossier — narrative clusters, price-impact dots, and the live Signal Lab.
Open full dossier

Forensic research, not investment advice. Scores reflect how the narrative holds up against the filings as of 2026-07-02.